Skip to content
← Full study record

NCT02001623 · MORE INFO

Limitations, agreements, and source contact

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors · Source last updated 2021-12-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
All proposed publications and presentations shall be submitted to the sponsor for its review at least 30 days before such presentation or publication is submitted to any third party.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
clinicaltrials@genmab.com
organization
Genmab A/S
phone
70202728
title
Clinical Trial Information
Complete source fields
certain Agreement
other Details
All proposed publications and presentations shall be submitted to the sponsor for its review at least 30 days before such presentation or publication is submitted to any third party.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
clinicaltrials@genmab.com
organization
Genmab A/S
phone
70202728
title
Clinical Trial Information

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice